Ipratropium detailed information
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 0 to 9% in vitro |
Metabolism | Hepatic |
Elimination half-life | 2 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C20H30NO3 |
Molar mass | 389.457 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Ipratropium (as ipratropium bromide, trade name Atrovent) is an anticholinergic drug administered by inhalation for the treatment of obstructive lung diseases. It acts by blocking muscarinic receptors in the lung, inhibiting bronchoconstriction and mucus secretion. It is a non-selective muscarinic antagonist, and does not diffuse into the blood, which prevents systemic side effects. Ipratropium is a derivative of atropine[1] but is a quaternary amine and therefore does not cross the blood-brain barrier, which prevents central side effects (anticholinergic syndrome).
Ipratropium is also combined with albuterol (salbutamol) (trade names Combivent and Duoneb) for the management of COPD and asthma. Ipratropium is also combined with fenoterol (trade names Duovent and Berodual N) for the management of asthma.
Side effects are as those for other anticholinergics.
Sources
- Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
- Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
- Boeringer-Ingelheim
Footnotes
- Pages with script errors
- CS1 maint: Multiple names: authors list
- CS1 maint: Unrecognized language
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Muscarinic antagonists
- Bronchodilators